Acasti Pharma EBIT Margin 2014-2023 | ACST
Current and historical EBIT (Earnings Before Interest & Taxes) margin for Acasti Pharma (ACST) over the last 10 years. The current EBIT profit margin for Acasti Pharma as of December 31, 2023 is .
| Acasti Pharma EBIT Margin Historical Data |
| Date |
TTM Revenue |
TTM EBIT |
EBIT Margin |
| 2016-11-30 |
$0.00B |
$-0.01B |
inf% |
| 2016-05-31 |
$0.00B |
$-0.00B |
inf% |
| 2016-03-31 |
$0.00B |
$-0.00B |
inf% |
| 2015-12-31 |
$0.00B |
$-0.01B |
inf% |
| 2015-09-30 |
$0.00B |
$-0.01B |
inf% |
| 2015-06-30 |
$0.00B |
$-0.01B |
inf% |
| 2015-03-31 |
$0.00B |
$-0.01B |
inf% |
| 2014-12-31 |
$0.00B |
$-0.01B |
inf% |
| 2014-06-30 |
$0.00B |
$-0.01B |
inf% |
| 2014-03-31 |
$0.00B |
$-0.01B |
inf% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.026B |
$0.000B |
|
Acasti Pharma Inc. is a biopharmaceutical company. It is focused on research, development and commercialization of krill oil based forms of omega-3 phospholipid therapies. CaPre (R), Acasti's only prescription drug candidate, is being developed to help prevent and treat hypertriglyceridemia. ONEMIA (R) is a medical food and currently Acasti's only commercialized product. Acasti Pharma Inc. is headquartered in Laval, Canada.
|
